Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2446 to 2460 of 9022 results

  1. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  2. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]

    In development Reference number: GID-TA11340 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    Awaiting development Reference number: GID-TA11956 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

    In development Reference number: GID-TA11772 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  5. Seladelpar for previously treated primary biliary cholangitis [ID6429]

    In development Reference number: GID-TA11540 Expected publication date:  09 July 2026

    Technology appraisal guidance
    In development

  6. MMprofiler for estimating risk in newly diagnosed multiple myeloma

    In development Reference number: GID-HTG10153 Expected publication date:  06 May 2027

    HealthTech guidance
    In development

  7. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    In development Reference number: GID-TA11565 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  8. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]

    Awaiting development Reference number: GID-TA11465 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development Reference number: GID-TA11235 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Bioinductive collagen scaffold (Regeneten) for rotator cuf repair

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  12. Focused Electrohydraulic Shockwaves for wound healing

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. Inserting a bupivicaine-collagen implant into a surgical wound for postoperative analgesia

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Human immunoglobulin with recombinant human hyaluronidase for maintenance treatment of multifocal motor neuropathy in people of any age TSID 12033

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]

    Awaiting development Reference number: GID-TA11716 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development